Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Aldeyra Therapeutics, Inc. (ALDX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.62-4.87%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ALDX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain stable executive and board leadership | A supporting condition in Aldeyra Therapeutics, Inc.'s published investment case. The stated target is no major unexpected leadership departures next 4 quarters. | Intact | unexpected key executive or director departures | 0 unexpected departures vs 0 target News shows planned director transition (Joyce) and new appointment (Deptula-Hicks). No unexpected key leadership departures reported. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development investment, not an established earnings compounder. The thesis is marked intact, but confidence is low and the business remains loss-making with high risk.
The evidence does not provide a valuation measure or a clear account of market expectations, so whether ALDX is cheap, fair, or expensive versus peers cannot be assessed. The September FDA rejection and the recent downward price reaction are part of the current backdrop, but the snapshot does not show how much of that news is reflected in expectations.
Near term, losses remain a key concern: ALDX reported net losses of $3.45 million in the first quarter and $5.45 million in the second quarter of 2026. Cash of $45.1 million at June 30 supports operations into 2029, while management continues to pursue regulatory and clinical development, including an FDA meeting expected in the fourth quarter of 2026 and a planned Phase 3 trial in 2027. The next results carry added uncertainty because the company is small and operates in a high-miss-rate industry.
The multi-year thesis hinges on whether management can make progress after the FDA rejection, including the planned dispute request for reproxalap and advancement of ADX-2191. It also depends on keeping losses and cash use under control. Near-term sector signals are mixed: strong results and guidance from healthcare bellwethers could support the sector backdrop, while weaker employment data or disappointing bellwether results could weaken it.
Over the next one to three years, ALDX remains a low-confidence, high-risk thesis centered on regulatory progress, pipeline execution, and cash discipline. The evidence is too thin to judge valuation expectations, and near-term results remain uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce cash from operations loss toward negative $5.1M |
| Cash from operations loss improved by $8.1M. |
| Intact |
| cash from operations worse than -5.1 million USD next quarter |
Cash from operations: $-4.589M FY2026-Q2; GAAP. Published target: cash from operations >= -5.1 million USD next quarter. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-4,589,422 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses toward negative $3.5M per quarter | A primary condition in Aldeyra Therapeutics, Inc.'s published investment case. The stated target is operating income >= -3.5 million USD next quarter. | Intact | operating income worse than -3.5 million USD next quarter | Operating income: $-5.851M FY2026-Q2; GAAP. Published target: operating income >= -3.5 million USD next quarter. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-5,850,507 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance clinical development and regulatory approval | A primary condition in Aldeyra Therapeutics, Inc.'s published investment case. The stated target is progress clinical trials and address FDA feedback. | Under Pressure | no meaningful progress on clinical trials or regulatory feedback | 3rd CRL received vs target of progress FDA issued a third CRL for reproxalap on March 16, 2026; company announced intent to appeal on September 29, 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.20 → $-0.28 · observed estimates
$0.02B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.20 | $15,799,400 | 5 / 5 |
| 2026-07-25 | $-0.20 | $15,799,400 | 5 / 5 |
| 2026-07-26 | $-0.20 | $15,799,400 | 5 / 5 |
| 2026-07-27 | $-0.20 | $15,799,400 | 5 / 5 |
| 2026-07-28 | $-0.20 | $15,799,400 | 5 / 5 |
| 2026-07-29 | $-0.20 | $15,799,400 | 5 / 5 |
| 2026-07-30 | $-0.20 | $15,799,400 | 5 / 5 |
| 2026-07-31 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-01 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-02 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-03 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-04 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-05 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-06 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-07 | $-0.23 | $8,400,000 | 3 / 3 |
| 2026-08-08 | $-0.23 | $8,399,250 | 4 / 4 |
| 2026-08-09 | $-0.26 | $11,199,000 | 4 / 3 |
| 2026-08-10 | $-0.26 | $11,199,000 | 4 / 3 |
| 2026-08-11 | $-0.26 | $11,199,000 | 4 / 3 |
| 2026-08-12 | $-0.26 | $11,199,000 | 4 / 3 |
| 2026-08-13 | $-0.28 | $16,798,500 | 4 / 2 |
| 2026-08-14 | $-0.23 | $8,400,000 | 3 / 3 |
| 2026-08-15 | $-0.23 | $8,400,000 | 3 / 2 |
| 2026-08-16 | $-0.23 | $8,400,000 | 3 / 2 |
| 2026-08-17 | $-0.23 | $8,400,000 | 3 / 2 |
| 2026-08-18 | $-0.23 | $8,400,000 | 3 / 3 |
| 2026-08-19 | $-0.23 | $8,400,000 | 3 / 3 |
| 2026-08-20 | $-0.23 | $8,400,000 | 3 / 3 |
| 2026-08-21 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-22 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-23 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-24 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-25 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-26 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-27 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-28 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-29 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-30 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-08-31 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-01 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-02 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-03 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-04 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-05 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-06 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-07 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-08 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-09 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-10 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-11 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-12 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-13 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-14 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-15 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-16 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-17 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-18 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-19 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-20 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-21 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-22 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-23 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-24 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-25 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-26 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-27 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-28 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-29 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-09-30 | $-0.28 | $8,399,250 | 3 / 3 |
| 2026-10-01 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-02 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-03 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-04 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-05 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-06 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-07 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-08 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-09 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-10 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-11 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-12 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-13 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-14 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-15 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-16 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-17 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-18 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-19 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-20 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-21 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-22 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-23 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-24 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-25 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-26 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-27 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-28 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-29 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-30 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-10-31 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-11-01 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-11-02 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-11-03 | $-0.28 | $8,400,000 | 3 / 3 |
| 2026-11-04 | $-0.28 | $8,400,000 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.